o9 is Raising the Bar for Enterprise Planning and Execution
DALLAS--(BUSINESS WIRE)-- o9, a leading AI-powered software platform for enterprise planning and execution, today announced new capabilities centered on specialized AI agents and self-learning models within its Digital Brain™ Platform. These advancements take intelligence, automation, and value-creation speed to the next level. The platform enables the digitization of processes from execution to long-range planning, across the supply chain, commercial, and P&L domains. It helps create a boundaryless operating model for optimized, synchronized decision-making in response to rapidly emerging and evolving market risks and opportunities.
Leading manufacturers, retailers, distributors and service providers across 30-plus industry verticals use the o9 Digital Brain™ to connect the islands of data and tribal knowledge into its patented Enterprise Knowledge Graph (EKG), enabling integrated planning and execution across the enterprise. o9 clients have reported value generation in the hundreds of millions per year, driven by inventory savings, cost of goods reduction, and improvements in customer service and productivity. The value proof points o9's clients are experiencing strongly validate o9's founding premise: enhancing enterprise planning and execution capabilities is the top value creation driver for any business navigating an increasingly volatile and complex world.
o9 invested in deep R&D and pilot programs with strategic clients to develop the following capabilities, which are now generally available.
Specialized o9 AI Agents for Planning and Execution
The Digital Brain now features specialized AI agents that enhance the productivity and expertise of management, planners, and individuals in front-line operations roles. o9 built these AI Agents by combining generative and agentic AI with its patented Enterprise Knowledge Graph (EKG), which connects data and tribal knowledge into a system of record of digital knowledge. These new AI Agents can analyze large volumes of data to identify risks and opportunities while answering key management questions that o9 refers to as the 3Ws: What happened and why? What is likely to happen? What cross-functional actions should be taken to improve the plan?
Performance Post-Game-Analysis (PGA) Solutions with Inbuilt Learning Models for Continuous Improvement
o9's PGA solutions powered by inbuilt learning models, provide insights into why the execution deviated from the plan and where the value leakage is happening. These capabilities are the ultimate catalyst for driving continuous improvement. The o9 PGA solutions include automated identification of value leakage and performance gaps, root-cause analysis algorithms, and AI-powered storytelling.
Self-Service Fast Innovation Platform: Enabling Enterprises to Own the Improvement and Drive Change Faster
This new offering will allow o9 clients to improve and extend capabilities within their existing o9 Digital Brain™ Platform through a self-service model. Users can continuously improve, innovate, and be in control of their own use of the platform to fine-tune capabilities and drive adoption of business processes. No-code and low-code AI agents will make it easier for innovation to leverage the platform's flexibility. Features include the ability to continuously extend and improve deployed solutions, build unique differentiated capabilities into standard processes, and modernize legacy applications.
Powered by these innovations, o9 is helping enterprises to build highly effective boundless operating models to drive performance excellence in highly volatile and fast-changing environments.
To learn more, visit www.o9solutions.com.
About o9
o9 is a leading AI-powered platform for integrated business planning and decision-making for the enterprise. Whether it is driving demand, aligning demand and supply, or optimizing commercial initiatives, any planning process can be made faster and smarter with o9's AI-powered digital solutions. o9 brings together technology innovations—such as graph-based enterprise modeling, big data analytics, advanced algorithms for scenario planning, collaborative portals, easy-to-use interfaces and cloud-based delivery—into one platform. For more information, please visit www.o9solutions.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone SHANGHAI & CAMBRIDGE, Mass., June 30, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing. Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths globally each year 1, highlighting a critical unmet medical need. In China, there are over 350,000 new cases each year. The disease is associated with a poor prognosis, particularly in advanced stages where the five-year survival rate is less than 10%. There are currently no approved therapies specifically targeting FGFR2b overexpression in gastric cancer in China. "Bemarituzumab is the first FGFR2b inhibitor to demonstrate a statistically and clinically significant overall survival benefit in a randomized Phase 3 trial for the first-line treatment of FGFR2b-positive gastric cancer," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "The success of the global Phase 3 FORTITUDE-101 study highlights the potential of bemarituzumab to redefine the standard of care for a patient population that has faced poor outcomes with existing therapies. We are proud to have contributed meaningfully to this pivotal trial, including a substantial number of patients enrolled in China. Based on these results, and the regulatory Breakthrough Designation, we plan to move rapidly toward regulatory submission in China to bring this transformative therapy to patients as quickly as possible." The most common treatment-emergent adverse events (>25%) in patients treated with bemarituzumab plus chemotherapy were reduced visual acuity, punctate keratitis, anaemia, neutropenia, nausea, corneal epithelium defect and dry eye. While ocular events were consistent with the Phase 2 experience and observed in both arms, they occurred with greater frequency and severity in the Phase 3 bemarituzumab arm. Detailed results from the trial will be shared at a future medical meeting. Zai Lab holds the development and commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan. Bemarituzumab has been granted Breakthrough Therapy designation by the China Center for Drug Evaluation of the National Medical Products Administration for the treatment of FGFR2b-positive gastric and gastroesophageal junction adenocarcinoma. A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with data readout anticipated in H2 2025. About FGFR2b The FGFR2b protein (also known as fibroblast growth factor receptor 2b) is an emerging biomarker which, when overexpressed, promotes aberrant signaling leading to tumor cell proliferation.2 The FGFR2b protein is overexpressed by G/GEJ tumor cells in approximately 38% of patients with advanced G/GEJ cancer. FGFR2b protein overexpression is defined as 2+/3+ staining intensity on tumor cell membrane, as detected by immunohistochemistry (IHC) testing. In approximately 16% of patients with advanced G/GEJ cancer, FGFR2b protein overexpression is observed on ≥10% of tumor cells by IHC.3 About FORTITUDE-101 FORTITUDE-101 is a randomized, multi-center, double-blind, placebo-controlled Phase 3 study of bemarituzumab plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line therapy in advanced G/GEJ cancer with FGFR2b overexpression. The FORTITUDE-101 trial spanned 300 sites across 37 countries, with 547 patients enrolled. The primary outcome measure of the trial is overall survival in patients with FGFR2b ≥10% 2+/3+ tumor cell staining. Key secondary outcome measures include progression-free survival and overall response rate. Candidates were excluded from the trial if they were known to be human epidermal growth factor receptor 2 (HER2) positive. FORTITUDE-101 included more comprehensive ocular-related monitoring than previous studies of bemarituzumab. About Gastric Cancer in China Gastric cancer is the fifth most common cancer worldwide, while China bears one of the highest gastric cancer burdens in the world with an estimated 358,700 new cases and 260,400 deaths annually.4 In China, approximately 80% of gastric cancer patients are diagnosed at an advanced or metastatic stage5. For those diagnosed with Stage IV gastric cancer, the overall 5-year survival rate is less than 10%6. Patients with advanced gastric and GEJ cancer that overexpress the FGFR2b protein may be associated with poor prognosis7-10. About Zai Lab Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements regarding the prospects and plans for developing and commercializing bemarituzumab, the potential benefits of bemarituzumab, and the potential treatment of gastric and gastroesophageal junction cancer. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at REFERENCES Bray F, et al. CA Cancer J Clin. 2024;74(3);229-263 Wainberg ZA, et al. Lancet Oncol. 2022;23(11):1430-40 Rha SY, et al. JCO Precis Oncol. 2025; 9 (e2400710). DOI:10.1200/PO-24-00710 Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. Health Commission of The People's Republic Of China N. National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):207-237. Li HQ, Zhang H, Zhang HJ, Wang YX, Wang XB, Hou HF. Survival of gastric cancer in China from 2000 to 2022: A nationwide systematic review of hospital-based studies. J Glob Health 2022;12:11014. Catenacci D, et al. Presented at American Society of Clinical Oncology; June 4-8, 2021; Online Virtual Scientific Program. Abstract 4010. Ahn S, et al. Mod Pathol. 2016;29:1095-1103. Ishiwata T. Front Biosci (Landmark Ed). 2018;23:626-639. Wainberg ZA, et al. Lancet Oncol. 2022;23:1430-1440. View source version on Contacts For more information, please contact: Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 / Media: Shaun Maccoun / Xiaoyu Chen+1 (857) 270-8854 / +86 185 0015 / Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Notification of Availability of Rémy Cointreau 2024-25 Universal Registration Document
PARIS, June 30, 2025--(BUSINESS WIRE)--Regulatory News: Rémy Cointreau's (Paris:RCO) 2024-25 Universal Registration Document was filed with the French Financial Markets Authority (AMF) in the European Single Electronic Format (ESEF) on Monday, June 30, 2025, under the reference number D.25-0497. The document is publicly available under the current regulatory conditions and can be accessed on Rémy Cointreau's website at in both French and English, within the Finance / Publications and Events / Annual reports and Registration documents' section. It is also available on the AMF website at in French. The Universal Registration Document includes in particular: the annual financial report as of March 31, 2025, the report of the Board of Directors on corporate governance, the Statutory Auditors' reports, the statement of Auditors' fees, the description of the share buyback program the sustainability report. About Rémy Cointreau All around the world, there are clients seeking exceptional experiences; clients for whom a wide range of terroirs means a variety of flavors. Their exacting standards are proportional to our expertise – the finely-honed skills that we pass down from generation to generation. The time these clients devote to drinking our products is a tribute to all those who have worked to develop them. It is for these men and women that Rémy Cointreau, a family-owned French Group, protects its terroirs, cultivates exceptional multi-centenary spirits and undertakes to preserve their eternal modernity. The Group's portfolio includes 14 singular brands, such as the Rémy Martin and LOUIS XIII cognacs, and Cointreau liqueur. Rémy Cointreau has a single ambition: becoming the world leader in exceptional spirits. To this end, it relies on the commitment and creativity of its 1,856 employees and on its distribution subsidiaries established in the Group's strategic markets. Rémy Cointreau is listed on Euronext Paris. View source version on Contacts Investor relations: Célia d'Everlange / investor-relations@
Business Wire
42 minutes ago
- Business Wire
Sinclair Names Matt Hamilton Vice President and General Manager of Boise Stations KBOI, KNIN & KYUU
BOISE, Idaho--(BUSINESS WIRE)--Sinclair today announced that Matt Hamilton has been appointed Vice President and General Manager of KBOI/CBS, KNIN/FOX and KYUU/CW+, Sinclair's owned and/or operated television stations in Boise. Hamilton most recently served as Market Sales Manager for the stations, where he successfully led multiplatform revenue generation and sales team development. 'We are thrilled to elevate Matt; his extensive media experience, combined with his strategic mindset and collaborative leadership style, make him the ideal choice to lead the Boise stations,' said Rob Weisbord, COO and President of Local Media. Prior to joining Sinclair in 2024, Hamilton held senior sales leadership roles at KVVU and SSSEN/Las Vegas; WGBA and WACY/Green Bay; KIVI and KSAW/Boise and Twin Falls; iHeartMedia/Portland; KPTV and KPDX/Portland; KOIN/Portland and the Oregonian Media Group/Portland. 'I'm honored for the opportunity to lead this talented team into the next chapter of growth and excellence. We will continue to uphold Sinclair's commitment to super-serving the community, engaging our audiences with high-quality local content, and providing Treasure Valley businesses with premium and strategic marketing solutions to accelerate growth and help them thrive,' said Hamilton. Hamilton is a graduate of Western Washington University, where he earned a Bachelor of Arts degree in English and Secondary Education. About Sinclair: Sinclair, Inc. (Nasdaq: SBGI) is a diversified media company and a leading provider of local news and sports. The Company owns, operates and/or provides services to 185 television stations in 85 markets affiliated with all major broadcast networks; owns Tennis Channel, the premium destination for tennis enthusiasts; multicast networks CHARGE, Comet, ROAR and The Nest; and the nation's largest streaming aggregator of local news content, NewsON. Sinclair's AMP Media produces a growing portfolio of digital content and original podcasts. Additional information about Sinclair can be found at
